Abstract
Serum thyroglobulin monitoring along with anatomic and functional imaging play key roles in the surveillance of patients with differentiated thyroid cancer after initial treatment. Among patients with a disease stage justifying thyroid remnant ablation or with suspected metastatic disease, radioiodine whole-body scans are essential in the months after surgery. For patients with low to moderate-risk cancers, ultrasonography of the neck (with measurement of serum thyroglobulin on thyroid hormone replacement) are the best initial diagnostic modalities, and are often the only tests required. In individuals suspected of having distant metastases, CT, MRI, and 18F-FDG PET can make important contributions in localizing residual disease and monitoring its progression and responses to therapy, provided they are used in the appropriate setting.
Original language | English (US) |
---|---|
Pages (from-to) | 239-252 |
Number of pages | 14 |
Journal | Endocrinology and Metabolism Clinics of North America |
Volume | 48 |
Issue number | 1 |
DOIs | |
State | Published - Mar 1 2019 |
Keywords
- Cancer recurrence
- Differentiated thyroid cancer
- Serum thyroglobulin monitoring
- Thyroid cancer imaging
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology